Next, we analyzed patient cohorts with clinical data (GSE91061 for melanoma and ERP117672 for HCC) and found that PRMT3 expression is significantly higher in the anti-PD-1 response group compared to the non-response group (Supplementary Fig. S7D–E). The gene discussed is PRMT3; the disease is melanoma.